Induction chemotherapy followed by radical chemoradiotherapy for patients with stage IV non‐metastatic nasopharyngeal carcinoma: 11‐Year Experience in a tertiary centre

Introduction T4 nasopharyngeal carcinoma (NPC) with close proximity to critical organs at risk (OARs) is usually underdosed during radiotherapy in order to respect radiation constraints. N3 disease has high risk of distant metastasis. Induction chemotherapy (IC) provides advantages of sparing of OAR...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medical imaging and radiation oncology 2022-09, Vol.66 (6), p.853-865
Hauptverfasser: Choi, Wesley Yuen Lum, Lai, Jessica Wing Yu, Yu, Ellen Lok Man, Choy, Yiu Hei, Lam, Ying Na, Wong, Raymond Ka Yan, Cheng, Ashley Chi Kin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Introduction T4 nasopharyngeal carcinoma (NPC) with close proximity to critical organs at risk (OARs) is usually underdosed during radiotherapy in order to respect radiation constraints. N3 disease has high risk of distant metastasis. Induction chemotherapy (IC) provides advantages of sparing of OARs during subsequent chemoradiotherapy (CCRT) and early eradication of micrometastasis. However, factors predicting successes of IC in this patient group are not well‐studied. Methods 104 T4 or N3 NPC patients were retrospectively reviewed during 2007–2018. They were planned for IC followed by CCRT using intensity‐modulated radiotherapy. Results In the whole group, five‐year failure‐free survival (FFS), locoregional failure‐free survival (LRFS), distant failure‐free survival (DFFS) and overall survival (OS) were 40.9%, 45.7%, 46.9% and 53.6% respectively. Isolated marginal failure rate was 5% (4/80) among patients with primary tumours located close to critical OARs. Pre‐IC gross tumour volume primary (GTVp) total volume > 110 cm3 correlated with worse five‐year LRFS (OR 6.37, P = 0.008), DFFS (OR 8.89, P = 0.003) and OS (OR 50.12, P 
ISSN:1754-9477
1754-9485
DOI:10.1111/1754-9485.13400